Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. - Hart LL; Im SA; Tolaney SM; Campone M; Pluard T; Sousa B; Freyer G; Decker T; Kalinsky K; Sopher G; Gao M; Hu H; et al. (European journal of cancer (Oxford, England : 1990), 2025)